Please login to the form below

Not currently logged in
Email:
Password:

Takeda files block on generic diet pill launch

Contrave is succumbing to patent attacks just months after being approved

TakedaOrexigen and its partner Takeda have taken Actavis to court to block a generic version of the firms' diet pill Contrave.

The lawsuit alleges that the generic drugmaker Actavis has infringed patents on Orexigen and Takeda's new weight-loss treatment Contrave (naltrexone and bupropion).

The treatment was approved in September last year after a three-year delay, caused by requests by the FDA for more data on cardiovascular safety.

In doing so it becomes the third weight-loss drug to be cleared by the FDA in recent years after a hiatus of more than a decade.

But despite being third to market among the new generation of obesity therapies after Eisai and Arena's Belviq (lorcaserin) and Vivus' Qsymia (phentermine/topiramate), both approved 18 months ago, Orexigen believes it will benefit from the market being developed by its competitors over the last year, which have yet to make significant sales gains despite the paucity of weight-loss therapies available on the market.

Contrave is indicated for use in tandem with a reduced-calorie diet and increased physical activity for chronic weight management in adults with a body mass index (BMI) of 30 or more, or 27 or more with an additional complication such as high blood pressure, diabetes or high cholesterol.

In March, an unauthorised release of early data from a Contrave study looking into risks of developing heart problems on taking the drug prompted the company to abandon the study.

The US is among the top five countries with the highest population of obese people, according to the World Health Organization, with more than 600 million people were obese worldwide as of 2014.

Actavis and Teva have both already filed for marketing approval of Qsymia's copycat version.

Article by
Ben Adams

8th June 2015

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
W2O Group

W2O Group is an integrated marketing agency with expertise in brand and digital strategy, creative development and communications services. We...

Latest intelligence

patients
Retaining reader value in plain language summaries of clinical studies
Balancing the risk of misinterpretation with the public’s ability to understand simplified plain-language summaries...
Can we talk about the ego-bias and chemicals influencing your target audience’s behaviour?
Over the Summer, the Page & Page team became fascinated by two books on this very subject. Two books from one author, Dean Burnett, an eminent neuroscientist, lecturing at Cardiff...
Paris
Making Europe a leader in bioscience: boosting trust and opening minds
A vision of Paris as Europe's leading hub for life sciences innovation...

Infographics